Fingerprint
Dive into the research topics of 'Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-hodgkin lymphoma: Results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically